Intuitive Surgical (NASDAQ:ISRG) EVP Mark Brosius Sells 46 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Mark Brosius sold 46 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $361.23, for a total value of $16,616.58. Following the completion of the transaction, the executive vice president owned 835 shares in the company, valued at $301,627.05. This represents a 5.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Brosius also recently made the following trade(s):

• On Wednesday, September 9th, Mark Brosius sold 23 shares of Intuitive Surgical stock. The stock was sold at an average price of $350.20, for a total value of $8,054.60.
• On Friday, August 21st, Mark Brosius sold 77 shares of Intuitive Surgical stock. The shares were sold at an average price of $375.57, for a total value of $28,918.89.
• On Wednesday, August 19th, Mark Brosius sold 77 shares of Intuitive Surgical stock. The stock was sold at an average price of $394.26, for a total value of $30,358.02.
• On Monday, August 17th, Mark Brosius sold 77 shares of Intuitive Surgical stock. The stock was sold at an average price of $390.67, for a total value of $30,081.59.
• On Friday, July 31st, Mark Brosius sold 28 shares of Intuitive Surgical stock. The shares were sold at an average price of $351.00, for a total transaction of $9,828.00.
• On Wednesday, July 29th, Mark Brosius sold 28 shares of Intuitive Surgical stock. The shares were sold at an average price of $360.21, for a total transaction of $10,085.88.
• On Monday, July 27th, Mark Brosius sold 28 shares of Intuitive Surgical stock. The stock was sold at an average price of $344.00, for a total transaction of $9,632.00.
• On Friday, June 12th, Mark Brosius sold 25 shares of Intuitive Surgical stock. The shares were sold at an average price of $414.13, for a total transaction of $10,353.25.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock traded up $3.08 on Wednesday, reaching $353.24. The company had a trading volume of 2,393,647 shares, compared to its average volume of 2,438,106. The firm’s 50 day moving average price is $379.70 and its two-hundred day moving average price is $426.25. The firm has a market cap of $124.79 billion, a PE ratio of 40.46, a PEG ratio of 2.77 and a beta of 1.47. Intuitive Surgical, Inc. has a 52-week low of $328.57 and a 52-week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, topping the consensus estimate of $2.48 by $0.32. The firm had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The business’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.81 EPS. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: A large meta-analysis found that da Vinci robotic-assisted surgery was associated with statistically significant improvements across 13 common benign conditions, including shorter hospital stays and faster returns to work versus laparoscopic and open surgery. The findings could support continued hospital adoption of Intuitive’s systems. New meta-analysis on da Vinci surgery outcomes
• Positive Sentiment: Analysts continue to view ISRG favorably. BTIG reaffirmed its Buy rating with a $469 price target, while other recent targets listed by Quiver Quantitative are materially above the current trading range. BTIG reaffirms Buy rating
• Positive Sentiment: Commentary at the Wells Fargo Healthcare Conference and related analyst coverage highlighted Intuitive’s long-term growth opportunity, innovation pipeline and expanding installed base. Articles also describe ISRG as trading at its cheapest valuation in roughly a decade, which may attract value-oriented investors despite near-term risks. Analyst views on Intuitive Surgical
• Neutral Sentiment: Investor discussions remain focused on the company’s strong margins, revenue growth and resilience, but also question whether the earnings multiple is justified while procedure trends moderate. ISRG earnings and procedure slowdown discussion
• Negative Sentiment: Recent coverage points to decelerating U.S. procedure growth, competitive pressure and possible effects from GLP-1 drugs. Rising costs and uncertainty around future growth have contributed to the stock’s recent weakness. Why ISRG underperformed the broader market
• Negative Sentiment: Reported insider activity shows numerous sales and no insider purchases over the past six months, a signal that may weigh on sentiment even though such transactions do not necessarily reflect management’s business outlook.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ISRG shares. Oppenheimer raised Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 price objective for the company in a research note on Wednesday, August 12th. Raymond James Financial reissued an “outperform” rating and set a $483.00 target price (down from $577.00) on shares of Intuitive Surgical in a research note on Friday, July 17th. Leerink Partners lowered their target price on Intuitive Surgical from $573.00 to $454.00 and set an “outperform” rating for the company in a report on Friday, July 17th. Bank of America dropped their target price on Intuitive Surgical from $520.00 to $515.00 in a research report on Friday, June 12th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $487.00 price target (down from $654.00) on shares of Intuitive Surgical in a research note on Friday, July 17th. Twenty-two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $508.68.

Institutional Trading of Intuitive Surgical

Large investors have recently modified their holdings of the stock. California State Teachers Retirement System grew its stake in Intuitive Surgical by 39,531.1% during the 2nd quarter. California State Teachers Retirement System now owns 213,725,958 shares of the medical equipment provider’s stock worth $84,994,539,000 after purchasing an additional 213,186,670 shares in the last quarter. Norges Bank purchased a new stake in Intuitive Surgical during the 4th quarter worth about $2,856,987,000. Bank of New York Mellon Corp acquired a new stake in Intuitive Surgical in the 2nd quarter valued at about $1,335,753,000. J. Stern & Co. LLP raised its position in Intuitive Surgical by 18,504.6% in the 4th quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider’s stock valued at $1,204,788,000 after purchasing an additional 2,115,814 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in shares of Intuitive Surgical by 1,043.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,342,121 shares of the medical equipment provider’s stock valued at $760,124,000 after buying an additional 1,224,734 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc is a medical technology company that develops and manufactures robotic-assisted surgical systems and related products. Its technology is designed to support surgeons during minimally invasive procedures by providing enhanced visualization, instrument control and dexterity.

The company’s principal product is the da Vinci Surgical System, which is used across a range of specialties, including general surgery, urology, gynecology, cardiothoracic surgery and other procedures.